Neonatal urinary tract infectious disease

Summary

Neonatal urinary tract infectious disease (MONDO:0001791) is a disease. A subtype of bacterial urinary tract infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neonatal urinary tract infectious disease
Mondo ID	MONDO:0001791
DOID	DOID:1375
SNOMED CT	12301009
UMLS	C0235815
MedGen	536451
Is cancer (heuristic)	no

Also known as: urinary tract infection of newborn

Disease family

This is a subtype of bacterial urinary tract infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial urinary tract infection › neonatal urinary tract infectious disease

Related subtypes (7): acute cystitis, urinary bladder tuberculosis, ureter tuberculosis, urethritis, renal tuberculosis, pyelonephritis, gonococcal cystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.